|
Synonyms: VHB-937 | VHB937
Compound class:
Antibody
Comment: Lifonebart (VHB937) is a fully human anti-TREM2 monoclonal antibody, with agonist activity at TREM2 on microglia [2]. It was designed for potential to treat inflammation-associated neurodegenerative conditions.
Peptide sequences for the heavy and light chains of lifonebart match sequences that are claimed in patent US11492402B2, specifically for antibody clones with the code name MOR044698 [1]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Brand V, Feuerbach D, Gasparini F, George N, Schaadt E, Shimshek D, Srinivas H, Waldhuber M, Wilken R. (2022)
TREM2 stabilizing antibodies. Patent number: US11492402B2. Assignee: Novartis AG. Priority date: 14/10/2019. Publication date: 08/11/2022. |
|
2. Stangel M, Feuerbach D, Shimshek D, Gasparini F, Galimberti I, George Nm Peraus G, Sovago J. (2024)
VHB937, a TREM2 Stabilizing and Activating Antibody Strongly Reduces Pathology After Peripheral Administration in a Broad Range of Animal Models for Neuroinflammation and Neurodegeneration (P4-4.004). Neurology, 102 (7_supplement_1): 5160. DOI: 10.1212/WNL.0000000000205610 |